Purified NA/LE Anti-Human HER2 Trastuzumab Biosimilar

BD Pharmingen™ Purified NA/LE Anti-Human HER2 Trastuzumab Biosimilar

Name: Purified NA/LE Anti-Human HER2 Trastuzumab Biosimilar
Brand: BD Pharmingen™
SKU: 569599

Clone Trastuzumab.rMAb (also known as Trastuzumab Biosimilar)

(RUO)

Inhibition of Human SK-BR-3 tumor cell proliferation by treatment with Trastuzumab Biosimilar.rMAb. Cells from the Human SK-BR-3 (Breast adenocarcinoma, ATCC® HTB-30™) cell line were treated with different doses of either Purified NA/LE Human IgG1, κ Isotype Control (Cat. No. 569605; Black Line) or Purified NA/LE Human Anti-Human ErbB2/HER-2 (CD340) Trastuzumab Biosimilar (Cat. No. 569599; Red Line) as shown with cell viability measured by an MTT Assay at OD 570 nm absorbance.

Spectrum Viewer

Protocol Library

Scientific Resources

Product Details

Brand: BD Pharmingen™

Alternative Name: ERBB2; proto-oncogene c-ErbB-2; HER-2; HER2; HER-2/neu; NEU; CD340

Reactivity: Human (QC Testing)

Isotype: Human IgG1, κ

Immunogen: A431 Cell Line Expressing EGFR

Application: Flow cytometry (Routinely Tested), Inhibition (Tested During Development)

Concentration: 1.0 mg/ml

Entrez Gene ID: 2064

Storage Buffer: No azide/low endotoxin: Aqueous buffered solution containing no preservative, 0.2 µm sterile filtered. Endotoxin level is ≤0.01 EU/µg (≤0.001 ng/µg) of protein as determined by the LAL assay.

Regulatory Status: RUO

Preparation And Storage

Store undiluted at 4°C. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. This preparation contains no preservatives, thus it should be handled under aseptic conditions.

Product Notices

Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
Since applications vary, each investigator should titrate the reagent to obtain optimal results.
Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
An isotype control should be used at the same concentration as the antibody of interest.
For U.S. patents that may apply, see bd.com/patents.

Companion Products

Stain Buffer (FBS) RUO

Size 500 mL Cat No. 554656

Stain Buffer (BSA) RUO

Size 500 mL Cat No. 554657

Purified NA/LE Human IgG1, κ Isotype Control RUO

Size 0.5 mg Cat No. 569605

569599 Rev. 1

Antibody Details

Trastuzumab.rMAb

The Trastuzumab.rMAb (also known as Trastuzumab Biosimilar.rMAb) is a research grade, chimeric recombinant human IgG1 kappa antibody that specifically recognizes the extracellular domain of Human Epidermal Growth Factor Receptor 2 (also known as HER2, HER-2, ErbB2, NEU, or CD340) similarly to the therapeutic Trastuzumab antibody. The Trastuzumab.rMAb uses the same variable region sequences as Trastuzumab, combined with constant region sequences derived from consensus sequences of human IgG1, kappa. Trastuzumab is a humanized therapeutic monoclonal antibody that was originally made by inserting the immunoglobulin (Ig) variable region sequences of the human HER-2-specific mouse monoclonal, 4D5. HER2 is a ~185 kDa type I transmembrane glycoprotein that is encoded by ERBB2 (erb-b2 receptor tyrosine kinase 2) which belongs to the ERBB family of receptor tyrosine kinases that includes EGFR (HER1), HER3, and HER4. Members of this receptor subfamily mediate the proliferation and differentiation of normal cells. Although HER2 has no identified direct-binding ligand, it forms signaling heterodimeric receptors with other ligand-bound ERBB family members. HER2 activates intracellular signaling pathways including MAPK and PI-3K through its cytoplasmic tyrosine kinase-containing region. HER2 is expressed by bone marrow mesenchymal stem cells. It is overexpressed and plays a significant role in the development of multiple human cancers including some leukemias, neuroblastomas, and carcinomas.

The Trastuzumab.rMAb is intended for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.

569599 Rev. 1

Format Details

NA/LE

NA/LE refers to the culture and purification methods and buffer used to produce purified antibodies with no azide and low endotoxin: Aqueous buffered solution containing no preservative, 0.2µm sterile filtered. Endotoxin level is ≤0.01 EU/µg (≤0.001 ng/µg) of protein as determined by the LAL assay.NA/LE are perfectly suited to be used in culture or in vivo (for nonhuman studies) for functional assays — blocking, neutralizing, activation or depletion — where the presence of azide may damage cells or exogenous endotoxin may signal or activate cells.

Format: NA/LE

569599 Rev.1

Citations & References

Development References (3)

Carter P, Presta L, Gorman CM, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy.. Proc Natl Acad Sci U S A. 1992; 89(10):4285-9. (Biology). View Reference
Goldenberg MM. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.. Clin Ther. 1999; 21(2):309-18. (Biology). View Reference
Stancovski I, Hurwitz E, Leitner O, Ullrich A, Yarden Y, Sela M. Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth.. Proc Natl Acad Sci USA. 1991; 88(19):8691-5. (Biology). View Reference

569599 Rev. 1

Please refer to Support Documents for Quality Certificates

Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described

Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims. Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.